Barricade Therapeutics
Fort Worth, US · Delaware corporation · 1 known investors
Barricade Therapeutics is a biotech company focused on oncology drug development, working to advance cancer treatments through evidence-based clinical pharmacology.
Founders & leadership
NC
Neil C. ThaparinCo-Founder, Board Chairman, CEO & Chief Scientific OfficerNeil C. Thapar is co-founder, board chairman, CEO, and chief scientific officer of Barricade Therapeutics, a biotech company developing cancer treatments. He has extensive background in drug development, clinical pharmacology, pharmacokinetic modeling, and analytical chemistry methods across preclinical and clinical stages.
JW
John WallinginCo-Founder, SVP, CMCHe has prior experience in pharmaceutical development, including active pharmaceutical ingredient formulation, solid oral and parenteral drug product development, and CMC regulatory strategy for IND, NDA, and marketing authorization filings.
ME
Mariam E. MorrisChief Operating Officer
SJ
Scott JordanChief Financial Officer
Investors · 1
Reported raises · per SEC filings
Form D private placements$100K disclosed across 1 round · 2026
▶$100KraisedJun 2026 · 1 investors · BiotechnologyRule 506(c)
▶$100KraisedJun 2026 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Neil ThaparExecutive Officer
- Amount sold
- $100K
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapCybrexa, Inc.4 shared keywordsCybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.
Parabilis Medicines4 shared keywordsHelicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules. The platform uses AI and simulation to engineer helical peptides with non-canonical amino acids for precision binding across a range of therapeutic applications.
Dialectic Therapeutics4 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Bicycle4 shared keywordsBicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers. Beyond oncology, it collaborates with pharmaceutical partners and academic groups to apply the technology to other therapeutic areas including anti-infective, cardiovascular, ophthalmology, dementia, CNS, neuromuscular and respiratory conditions.
Obsidiantx3 shared keywordsObsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.
Companies competing with Barricade Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Barricade Therapeutics do?
- Barricade Therapeutics is a biotech company focused on oncology drug development, working to advance cancer treatments through evidence-based clinical pharmacology.
- Who founded Barricade Therapeutics?
- Barricade Therapeutics was founded by Neil C. Thapar, John Walling.
- Who are Barricade Therapeutics's investors?
- Barricade Therapeutics's investors include Green Park & Golf Ventures.
- How much funding has Barricade Therapeutics raised?
- Barricade Therapeutics has disclosed $100K raised across 1 round.
- Where is Barricade Therapeutics headquartered?
- Barricade Therapeutics is headquartered in Fort Worth, US.